Exploring the transformative potential of FDA-approved CAR T-cell therapies cilta-cel and ide-cel for relapsed/refractory multiple myeloma. Marc Braunstein, MD, PhD, shares insights from 90+ oncologists on their application in early relapse. Sign up now to access the full article: https://hubs.li/Q03cnLyh0 #NYU #oncology #cancernews #CancerAwareness #myeloma #mmsm #multiplemyeloma #exclusive NYU Langone Health
Targeted Oncology
在线音视频媒体
Cranbury Township，New Jersey 59,004 位关注者
The Community Resource in Targeted Therapies
关于我们
TargetedOnc.com provides content focused on next generation therapeutics and their molecular targets. As the field of oncology continues to trend toward systemic biology and molecular aberrations, the challenge facing many oncologists is staying recent and up-to-date with the future of cancer therapeutics. TargetedOnc.com focuses on the next stage of cancer development, focusing on cutting edge therapies and their biological targets. Content is organized by therapy type, target, peer-reviewed content, and conference coverage.
- 网站
-
https://targetedonc.com
Targeted Oncology的外部链接
- 所属行业
- 在线音视频媒体
- 规模
- 2-10 人
- 总部
- Cranbury Township，New Jersey
- 类型
- 上市公司
- 领域
- Oncology、Healthcare Communications、Healthcare、Cancer Research、Targeted Therapies、Community Oncology、Cancer、Cancer Treatment和Oncologists
地点
-
主要
获取路线
2 Clarke Dr
US，New Jersey，Cranbury Township
Targeted Oncology员工
动态
-
James W. Smithy, MD, MHS, and other oncologists discussed how their experience with immune-related adverse events in metastatic #melanoma has developed over time. #melsm | Memorial Sloan Kettering Cancer Center https://hubs.li/Q03cRQY10
-
In this interview, Frank J. Penedo, PhD from Sylvester Comprehensive Cancer Center explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs. https://hubs.li/Q03cYTk30
-
Nagashree Seetharamu, MD, MBBS, discusses how community practitioners should monitor the use of toripalimab for recurrent/metastatic nasopharyngeal carcinoma treatment. https://hubs.li/Q03bNdRj0
-
Catherine J. Lee, MD, MS, discussed the efficacy and safety results of various trials of approved agents for treating chronic #GVHD. https://hubs.li/Q03cMC6m0
-
During a live event, Sumanta K. Pal, MD, discusses the efficacy and safety findings from the CheckMate 274 trial of adjuvant nivolumab in patients with bladder cancer. #blcsm | City of Hope https://hubs.li/Q03cFfbx0
-
ST316, a first-in-class antagonist of the interaction between β-catenin and its co-activator BCL9, has demonstrated promising results in the phase 1 dose-escalation ST316-101 study in Wnt/β-catenin pathway-driven cancers. https://hubs.li/Q03cMhLf0
-
A trial of oral zelenirstat, a first-in-class N-myristoyltransferase inhibitor, dosed its first patient with relapsed/refractory #AML, according to a press release from Pacylex Pharmaceuticals, Inc. https://hubs.li/Q03cFb9c0
-
During a live event, Thach-Giao Truong, MD, moderated a discussion on treating a 78-year-old patient with metastatic #melanoma with immunotherapy. #melsm | Cleveland Clinic https://hubs.li/Q03cypnx0
-